Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Epstein Barr Virus (EBV) Infection clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07888088
Phase 1 Trial to Evaluate Safety and Immunogenicity of MVA-BN-EBV in Healthy Young Adults
Phase 1, single-center, randomized, placebo-controlled, double-blind clinical trial. Participants (N = 15) will receive a 2-dose schedule (1 vaccination on day 1 and day 28) randomized, receiving either MVA-BN-EBV (n = 12) or placebo (n = 3).
Gender: All
Ages: 18 Years - 30 Years
Updated: 2026-10-22
1 state
NCT07614282
Rituximab for PTLD Prevention in Solid Organ Transplant Recipients With EBV DNAemia
People who have received a solid organ transplant can develop ongoing Epstein-Barr virus (EBV) infection in the blood, which increases the risk of a serious cancer called post-transplant lymphoproliferative disorder (PTLD). This study will test whether rituximab, a drug approved by the U.S. Food and Drug Administration (FDA) for several immune-related conditions, can safely clear EBV from the blood and help prevent PTLD when lowering immune-suppressing medications is not possible or effective. The study includes an initial smaller group focused on determining whether EBV can be cleared, followed by a larger group designed to determine whether treatment lowers the risk of developing PTLD. Researchers will also monitor side effects, transplant organ health, and immune system changes to better understand treatment safety and benefit.
Gender: All
Ages: 18 Years - Any
Updated: 2026-09-17